Fig. 3

Transplanted mDASCs incorporated in damaged lung and differentiated into type I pneumocytes. a Distribution of transplanted GFP-labeled cells in lung parenchyma by direct fluorescence. Scale bar, 50 μm. b Immunostaining of GFP-labeled mDASCs with anti-GFP, anti-KRT5, and anti-P63 antibodies 7 days after transplantation. Scale bar, 20 μm. c Immunostaining of transplanted GFP-labeled mDASCs in the lung parenchyma with anti-GFP and anti-PDPN (type I alveolar cell marker) antibodies 14 days after transplantation. Scale bar, 20 μm. d Amplification inset in c indicates a regenerated alveolar structure. Scale bar, 10 μm. e Immunostaining of transplanted GFP-labeled mDASCs in the lung parenchyma with anti-GFP, anti-HOPX (type I alveolar cell marker), and anti-P63 antibodies 14 days after transplantation. Scale bar, 20 μm. f Immunostaining of transplanted GFP-labeled mDASCs in the lung parenchyma with anti-GFP and anti-AQP5 (type I alveolar cell marker) antibodies 14 days after transplantation. Scale bar, 20 μm. Arrows show the co-localization staining of GFP and indicated marker